IMDX IMDX
Company Profile ↓Company Overview
IMDX (IMDX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 27.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $4.05M (+115.6% YoY); net profit $-50.22M.
- Trailing 12 Months Year-on-year growth — revenue +115.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 27.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 27.24% |
| 1 Year: | 115.58% |
Stock Price Performance
| 1 Year: | +80.51% |
| 6 Months: | -25.26% |
| 3 Months: | +9.17% |
| 1 Month: | +1.42% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross6d ago
- RSI (14)50.94 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 27.2% over 5 years.
CONS
- Trading 41.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 16.00K | 143.00K | 555.00K | 503.00K | 1.12M | 2.03M | 984.00K | 3.59M | 380.00K | 237.00K | 67.00K | 297.00K | 463.00K | 429.00K | 176.00K | 104.00K | 115.00K | 2.14M | 518.00K | 260.00K | 32.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -222.00K | -46.00K | - | 79.00K | -394.00K | -866.00K | - | 247.00K | 31.00K | -269.00K | 10.00K | 272.00K | 248.00K | 45.00K | 50.00K | 50.00K | 1.32M | 350.00K | 139.00K | 15.00K |
| Operating Income | -1.37M | -1.41M | -2.41M | -2.93M | -2.53M | -2.58M | -4.53M | -3.59M | -6.83M | -3.91M | -4.23M | -3.02M | -4.00M | -5.46M | -5.26M | -8.43M | -8.77M | -6.24M | -6.27M | -11.36M | -13.57M | -13.60M | -35.68M | -3.02M | -1.63M | -1.71M | 5.85M | -8.29M | -6.51M | -9.27M | -4.63M | -13.52M | -6.80M | -9.84M | -11.05M | -4.41M |
| Net Income | -1.37M | -1.41M | -2.42M | -2.93M | -2.54M | -2.60M | -4.70M | -3.80M | -6.91M | -3.78M | -4.50M | -2.97M | -3.86M | -5.38M | -5.22M | -7.73M | -9.11M | -6.78M | -6.31M | -3.92M | -10.49M | -13.80M | -35.88M | -10.29M | -8.30M | -9.33M | 3.03M | -8.33M | -6.49M | -9.13M | -4.53M | -13.49M | -6.67M | -9.74M | -10.85M | -4.29M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.11 | -1.48 | -1.62 | 0.40 | -1.07 | -0.81 | -1.13 | -0.36 | -0.98 | -0.26 | -0.30 | -0.34 | -0.12 |
| R&D Expense | 1.12M | 886.00K | 1.09M | 1.69M | 1.20M | 1.36M | 1.83M | 2.00M | 1.84M | 1.46M | 2.32M | 1.53M | 1.34M | 1.51M | 1.62M | 2.16M | 3.23M | 2.62M | 1.80M | 3.36M | 2.54M | 3.14M | 4.59M | 2.01M | 2.44M | 1.47M | 2.13M | 2.44M | 2.19M | 2.31M | 2.45M | 2.82M | 2.92M | 3.28M | 3.88M | 4.95M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 1.22M | 2.20M | 958.00K | 1.50M | 1.88M | 4.05M |
| Gross Profit | - | - | - | - | - | - | -639.00K | 1.42M | -18.00K | 413.00K | 740.00K | 2.30M |
| Operating Income | -4.97M | -8.72M | -11.14M | -18.85M | -15.20M | -22.24M | -29.71M | -53.73M | -18.00M | -25.14M | -61.04M | -51.12M |
| Net Income | -4.99M | -8.73M | -11.17M | -19.38M | -15.75M | -22.43M | -29.93M | -64.10M | -72.90M | -27.78M | -60.66M | -50.22M |
| Diluted EPS | - | - | - | - | - | - | - | - | -13.25 | -3.75 | -4.66 | -1.65 |
| R&D Expense | 3.96M | 4.53M | 5.68M | 7.17M | 6.51M | 6.79M | 9.80M | 5.04M | 7.30M | 9.29M | 9.84M | 15.90M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 12.73M | 14.45M | 10.22M | 9.52M | 39.86M | 55.42M | 159.56M | 100.09M | 74.89M | 35.08M | 25.76M |
| Total Equity | 3.62M | -1.07M | 10.42M | 9.86M | 4.40M | 3.42M | 30.84M | 33.48M | 65.22M | 34.29M | 20.47M | -12.27M | -31.46M |
| Cash & Equivalents | 101.00K | 257.00K | 8.00M | 10.17M | 7.60M | 8.03M | 22.07M | 7.14M | 32.95M | 19.99M | 9.43M | 8.64M | 11.58M |
| Long Term Debt | - | - | - | - | 1.87M | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 2.31M | 4.58M | 5.81M | 6.09M | 9.02M | 21.94M | 94.35M | 60.50M | 49.30M | 47.35M | 57.22M |
| Current Liabilities | - | - | 2.31M | 4.28M | 4.45M | 5.56M | 4.44M | 9.00M | 14.12M | 12.11M | 7.19M | 7.28M | 12.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -4.23M | -7.52M | -13.38M | -11.65M | -19.71M | -25.98M | -35.94M | -45.57M | -23.32M | -20.69M | -22.18M |
| Investing Cash Flow | - | 315.00K | -181.00K | 843.00K | -31.00K | -12.41M | -11.75M | -13.96M | -4.34M | -932.00K | -512.00K | -3.19M |
| Financing Cash Flow | - | 11.65M | 9.88M | 9.97M | 12.11M | 47.87M | 22.80M | 78.36M | 35.81M | 12.19M | 20.43M | 28.07M |
| Capital Expenditure | -9.00K | -500.00K | -106.00K | -91.00K | -31.00K | -918.00K | -1.23M | -2.25M | -4.34M | -281.00K | -516.00K | -3.19M |
| Free Cash Flow | - | -4.73M | -7.63M | -13.48M | -11.68M | -20.63M | -27.21M | -38.19M | -49.91M | -23.61M | -21.20M | -25.37M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | -52.5% | 64.6% | -1.9% | 27.5% | 39.3% | 56.7% |
| Operating Margin % | - | - | - | - | - | - | -2,443.3% | -2,444.3% | -1,878.6% | -1,672.4% | -3,245.1% | -1,260.8% |
| Net Margin % | - | - | - | - | - | - | -2,461.5% | -2,916.2% | -7,609.8% | -1,848.4% | -3,225.0% | -1,238.5% |
| ROE % | 464.2% | -83.9% | -113.2% | -440.0% | -460.2% | -72.7% | -89.4% | -98.3% | -212.6% | -135.7% | 494.2% | 159.6% |
| ROCE % | - | -83.7% | -109.5% | -327.1% | -384.2% | -62.8% | -64.0% | -36.9% | -20.5% | -37.1% | -219.5% | -373.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IMDX
New Medicare policy allows more donor-DNA tests after transplants - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPeTU1S29JQ3VwMThSWDJSdUp4R3lPNE1jWGxMWWZTcXBJTGVoeGNIR1VKUVNOWk9tZ1lMY1NCSUNqT0VkVTJKa0hiV2FRSDZVdDRpLW1mSklUeUV0cGkyaDROTXdRaFNIdlJmZ3EzU3lvZE1QcXdSZktVdUU5UWRSYm9GaV94dzIwUnFvV0…
Insight Molecular Diagnostics Inc. Revenue Breakdown – NASDAQ:IMDX - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE1xRV92RHFMdmw3VHkxaVZWZmsxa0tqUGZTRDh5SjVyaDloVXhUcEFza1dUU3IzempiOVZpOWgxNm9vQ2VCVG94X0Zua2k4M29PdXJZYWpFM09ILVllOVQtcEU5VlAwZ1hLcTltMHlRSlYtY3NkRmlN?oc=5" target="_blank">Insight…
IMDX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE51eXFYbU1aaXYzSVJld2diRXctWEJPbmVkcC1wM21zRzFHNEhUZ0wzeF94czVjbXZZZkNaS3NLeHpOaTRGbkE?oc=5" target="_blank">IMDX</a> <font color="#6f6f6f">Finviz</font>…
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And FDA Catalyst - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxORmdZSllzdFhJazkwTVl0N1Fzay1LS2c2WDgwQ0JjT3BDZDN2Y0hmdi1ucmFXQlVvSjhjQ0hReEUzclo3aFZkVm1uc0RFWTktMnBJSnFlVnBWVjRSRUd1VEpnTXNGUW9pNEN4bEpZNHNMUlFQVmh5M1I0YnFaMUpuT0h2MHlrenF0eFFZem…
$IMDX stock is up 17% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOenFENWNUNlREYnpzblFOWExZRVdIdmhRSmRvdXhwMXprb0pBbHlkWDhrb1Z3UUFpaXQtWnZRSFNyWEZuSEctWU9RYzQtWkpXQjV4YXYxVm5ZMWg0RzlfbG9LX2JQY2tfU0g5ekJodUpxZEZQSWFyM0lJX3hzek54N1MzMFpTTkxTdms1Zn…
Earnings Preview: IMDX to Report Financial Results Post-market on August 10 - 富途牛牛
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOa0VBZmJ4T0REd1M5bEd5QW50c01zdGxGaWdkVXA4Vk4yeWhHVGhsbzdSTk1mYjhOTlpLc2diU0RpUnZpUkV6dEpzY3c1dUVGNEdwaUo5RExmbFcwZUxVczZhY0tFb3UxXzFPeGNXRUFCaHA2eHVXalpCaGdSazNEeFF1UTRxTVNWSXBBWV…
IMDX — Frequently Asked Questions
What is the current share price of IMDX?
As of 2026-08-05 17:25 PDT, IMDX trades at $5.00 on NASDAQ/NYSE. Its 52-week range is $2.40 to $8.48.
What is the P/E ratio of IMDX?
IMDX trades at a trailing price-to-earnings (P/E) ratio of -3.03.
Is IMDX a good stock to buy?
This page provides a data-driven analysis of IMDX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.